Published in J Clin Oncol on May 01, 1996
Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer (2006) 1.14
C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review. PLoS One (2015) 1.03
Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer (2004) 1.02
Diagnostic and prognostic biomarkers in melanoma. J Clin Aesthet Dermatol (2014) 0.98
Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol (2000) 0.97
Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. Oncoimmunology (2015) 0.85
The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. Oncoimmunology (2013) 0.85
Targeting T cells with bispecific antibodies for cancer therapy. BioDrugs (2011) 0.85
Melanoma biomarkers: Vox clamantis in deserto (Review). Oncol Lett (2010) 0.81
Influence of human immune cells on cancer: studies at the University of Colorado. Immunol Res (2013) 0.80
The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Front Immunol (2011) 0.78
Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial. J Transl Med (2003) 0.77
Melanoma immunotherapy. Cancer Biol Ther (2014) 0.76
Prognostic Significance of Lymphocyte Counts in Colon Cancer Patients Treated with FOLFOX Chemotherapy. World J Surg (2017) 0.75
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med (1998) 4.93
Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A (1999) 4.52
Age as prognostic factor in premenopausal breast carcinoma. Lancet (1993) 4.31
Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst (1991) 4.24
Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi's sarcoma. Lancet (1995) 3.81
Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells. Br J Cancer (1969) 2.96
Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer (1996) 2.95
Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood (1998) 2.93
Stimulation of lymphocytes by autologous leukaemic cells in acute leukaemia. Nature (1969) 2.75
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol (1994) 2.66
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res (1992) 2.64
Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst (1994) 2.58
Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet (2004) 2.55
Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer (2009) 2.52
Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science (1992) 2.41
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem (2001) 2.33
Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res (2001) 2.28
Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res (1999) 2.23
Diversity of V3 region sequences of human immunodeficiency viruses type 1 from the central African Republic. AIDS Res Hum Retroviruses (1993) 2.22
Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol (2007) 2.15
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol (2002) 2.15
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol (2004) 2.15
Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med (1990) 2.15
Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol (2009) 2.12
The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity (1995) 2.12
Rituximab in CD20 positive multiple myeloma. Leukemia (2007) 2.11
Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol (2010) 2.11
Thalidomide in hyperalgic pharyngeal ulceration of AIDS. Lancet (1990) 2.10
A multicenter study of treatment of primary CNS lymphoma. Neurology (2002) 2.04
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol (2002) 2.03
Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies? Ann Oncol (2011) 2.03
Long-term results of monthly inhaled pentamidine as primary prophylaxis of Pneumocystis carinii pneumonia in HIV-infected patients. Am J Med (1993) 2.02
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2001) 1.99
Epidemiological and virological influenza survey in Dakar, Senegal: 1996-1998. Am J Trop Med Hyg (2000) 1.96
ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Féderation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys (1991) 1.91
BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet (1997) 1.91
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol (2010) 1.91
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol (2010) 1.91
Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol (2001) 1.84
Cell-mediate cytotoxicity in vitro of human lymphocytes against a tissue culture melanoma cell line (igr3). J Immunol (1975) 1.82
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. Ann Oncol (2013) 1.82
Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol (1997) 1.77
Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer (2006) 1.73
Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet (1993) 1.72
Cosmetic sequelae after conservative treatment for breast cancer: classification and results of surgical correction. Ann Plast Surg (1998) 1.72
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol (2009) 1.71
Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J Natl Cancer Inst (1998) 1.71
Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol (2000) 1.71
Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J Clin Invest (1995) 1.70
Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. J Clin Oncol (2005) 1.70
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol (1997) 1.67
Mosquito vectors of the 1998-1999 outbreak of Rift Valley Fever and other arboviruses (Bagaza, Sanar, Wesselsbron and West Nile) in Mauritania and Senegal. Med Vet Entomol (2005) 1.67
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol (2010) 1.65
Added value of molecular targeted agents in oncology. Ann Oncol (2011) 1.65
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer (2013) 1.65
Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer (1999) 1.61
Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. Int J Radiat Oncol Biol Phys (1989) 1.61
Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer (1994) 1.60
Tyrosine-containing motif that transduces cell activation signals also determines internalization and antigen presentation via type III receptors for IgG. Nature (1992) 1.60
Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. Ann Oncol (2010) 1.59
The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet (2009) 1.59
Serum soluble interleukin-2 receptor concentrations as an independent prognostic marker in head and neck cancer. Lancet (2001) 1.58
Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol (2009) 1.57
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer (2008) 1.57
Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev (2011) 1.55
Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology. Leuk Res (1999) 1.55
Prognostic value of tumor regression during radiotherapy for head and neck cancer: a prospective study. Int J Radiat Oncol Biol Phys (1995) 1.52
No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer (1998) 1.52
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol (1992) 1.50
Characterization and function of T cell Fc gamma receptor. Immunol Rev (1981) 1.50
A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A (2001) 1.49
An interleukin 2/sodium butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis. Gastroenterology (1994) 1.49
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials. Leukemia (2007) 1.48
Differential modulation of stimulatory and inhibitory Fc gamma receptors on human monocytes by Th1 and Th2 cytokines. J Immunol (2001) 1.48
T-cell hybrids bear Fcgamma receptors and secrete suppressor immunoglobulin binding factor. Nature (1979) 1.47
Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol (2007) 1.47
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol (2007) 1.45
Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res (1996) 1.45
Soluble Fc gamma receptors. J Leukoc Biol (1993) 1.45
Heat and moisture exchanger vs heated humidifier during long-term mechanical ventilation. A prospective randomized study. Chest (1991) 1.43
Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV type 1 serological subtyping. AIDS Res Hum Retroviruses (1996) 1.42
Protracted continuous infusion of 5-fluorouracil in combination with doxorubicin, vincristine, and oral cyclophosphamide in advanced breast cancer. Cancer Invest (1996) 1.42
Enzyme-linked immunosorbent assay for screening monoclonal antibody production using enzyme-labeled second antibody. Methods Enzymol (1983) 1.42